Daniel Hoffman, MD
Dermatology · Williston, NDNPI 1205006897
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $854 of the $1,039 with a category attached, or 82.2%. 12 manufacturers reported payments, led by AbbVie at 30.2% of the total. 2025 is the largest year on record at $435, 4.8 times the $92 reported in 2020. That places this record below the midpoint for dermatology clinicians in ND, where the typical reported total is $1,206.
Across 47 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$314
- Lilly USA, LLC$211
- Sun Pharmaceutical Industries Inc.$116
- Johnson & Johnson$88
- Sanofi-aventis U.S. LLC$85
- Sanofi$65
- plus $159 from 6 others
What the payments were for
- Food & beverage$85482%
- Education$18518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $314 |
| Lilly USA, LLC | 10 | $211 |
| Sun Pharmaceutical Industries Inc. | 2 | $116 |
| Johnson & Johnson | 5 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Sanofi | 3 | $65 |
| Novartis | 3 | $64 |
| Strata Skin Sciences, Inc. | 2 | $35 |
| Boehringer Ingelheim | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Incyte Corporation | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $13 |
How this compares
$1,039 in reported general payments places this provider in the 45th percentile of 29 dermatology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 12 | $236,716 |
| Dupixent PenDupilumab | 14 | $51,547 |
| Fluocinonide | 60 | $2,929 |
| Clobetasol Propionate | 47 | $1,975 |
| Fluorouracil | 16 | $1,772 |
| Tacrolimus | 17 | $1,734 |
| Azelaic Acid | 13 | $1,405 |
| Ketoconazole | 62 | $1,404 |
| Desonide | 18 | $1,343 |
| Triamcinolone Acetonide | 80 | $1,226 |
| Fluocinolone Acetonide | 16 | $1,208 |
| Metronidazole | 22 | $1,021 |
| Betamethasone Dipropionate | 18 | $916 |
| Clindamycin Phosphate | 16 | $756 |
| Cefadroxil | 54 | $697 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Williston
- Imran AslamBismarck$280K
- Michael BlankinshipFargo$130K
- Mary LogueMinot$9K
- Rachel NessFargo$8K
- Margaret NewsomeMinot$8K
- Alexandra GeigerBismarck$4K
- Nicole SotoBismarck$4K
- Megan StrandBismark$3K
- Amanda BeehlerFargo$2K
- Natalie KollmanFargo$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.